MPM Bioimpact
BOSTON, MAfiles as MPM BIOIMPACT LLC
$1.6bn in 37 US stocks at the end of 30 June 2026. The top 10 are 55.3% of the money. It changed about 31.1% of the portfolio this quarter.
Value
$1.6bn
Stocks
37
Top 10 share
55.3%
Turnover
31.1%
What changed this quarter
New
Bought for the first time this quarter.
- Ultragenyx PharmaceuticalRARE2.9% of the fund
- BioAge LabsBIOA2.5% of the fund
- Taysha Gene TherapiesTSHA1.9% of the fund
- Zura BioZURA1.6% of the fund
- Adlai NortyeANL1.4% of the fund
- AnnexonANNX1.2% of the fund
- Entrada TherapeuticsTRDA0.6% of the fund
Added
Bought more of a stock they already held.
- Cullinan TherapeuticsCGEM10.8% of the fund+27%
- Relay TherapeuticsRLAY2.8% of the fund+2%
- Abivax SAABVX2.7% of the fund+214%
- Dyne TherapeuticsDYN2.6% of the fund+37%
- Belite BIOBLTE1.3% of the fund+56%
- Oric PharmaceuticalsORIC1.2% of the fund+4%
- Aclaris TherapeuticsACRS0.3% of the fund+166%
Cut
Sold some of their stake.
- Revolution MedicinesRVMD5.6% of the fund-3%
- Corcept TherapeuticsCORT4.1% of the fund-22%
- Edgewise TherapeuticsEWTX4.0% of the fund-2%
- DBV Technologies S ADBVT3.7% of the fund-30%
- Trevi TherapeuticsTRVI3.5% of the fund-7%
- AlumisALMS3.5% of the fund-15%
- uniQureQURE3.4% of the fund-10%
- MoonLake ImmunotherapeuticsMLTX1.9% of the fund-11%
- Stoke TherapeuticsSTOK1.4% of the fund-6%
- Tarsus PharmaceuticalsTARS1.2% of the fund-2%
- Bright Minds BiosciencesDRUG0.9% of the fund-5%
- Context TherapeuticsCNTX<0.1% of the fund-88%
- Werewolf TherapeuticsHOWL<0.1% of the fund-93%
Sold out
Sold their entire stake.
- Agios PharmaceuticalsAGIO-100%
- Xenon PharmaceuticalsXENE-100%
- EvommuneEVMN-100%
- CytokineticsCYTK-100%
- Corvus PharmaceuticalsCRVS-100%
- Climb BioCLYM-100%
- Arcutis BiotherapeuticsARQT-100%
- ZymeworksZYME-100%
- Viridian TherapeuticsVRDN-100%
- Engene Holdings-100%
- Allogene TherapeuticsALLO-100%
Holdings
- DBV Technologies S ADBVT
- Share
- 3.7%
- Value
- $60m
- Shares
- 3,666,284
-30%
- Abivax SAABVX
- Share
- 2.7%
- Value
- $45m
- Shares
- 336,347
+214%
- Adlai NortyeANL
- Share
- 1.4%
- Value
- $22m
- Shares
- 1,936,291
New
- Belite BIOBLTE
- Share
- 1.3%
- Value
- $21m
- Shares
- 137,208
+56%
- Forte Biosciences
- Share
- 1.3%
- Value
- $21m
- Shares
- 987,448
Held
- Bright Minds BiosciencesDRUG
- Share
- 0.9%
- Value
- $14m
- Shares
- 202,114
-5%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Cullinan TherapeuticsCGEM | 10.8% | $177m | 9,731,341 | +27% |
| Aktis OncologyAKTS | 9.5% | $156m | 4,835,872 | Held |
| LiquidiaLQDA | 6.7% | $111m | 1,386,174 | Held |
| Revolution MedicinesRVMD | 5.6% | $92m | 492,483 | -3% |
| Corcept TherapeuticsCORT | 4.1% | $67m | 771,028 | -22% |
| Edgewise TherapeuticsEWTX | 4.0% | $66m | 1,620,780 | -2% |
| Travere TherapeuticsTVTX | 3.9% | $64m | 1,122,731 | Held |
| DBV Technologies S ADBVT | 3.7% | $60m | 3,666,284 | -30% |
| Trevi TherapeuticsTRVI | 3.5% | $57m | 3,073,577 | -7% |
| AlumisALMS | 3.5% | $57m | 2,019,020 | -15% |
| uniQureQURE | 3.4% | $56m | 1,225,855 | -10% |
| Ultragenyx PharmaceuticalRARE | 2.9% | $47m | 1,418,215 | New |
| Relay TherapeuticsRLAY | 2.8% | $45m | 2,415,672 | +2% |
| Abivax SAABVX | 2.7% | $45m | 336,347 | +214% |
| Dyne TherapeuticsDYN | 2.6% | $43m | 1,922,093 | +37% |
| Dianthus TherapeuticsDNTH | 2.5% | $41m | 420,002 | Held |
| BioAge LabsBIOA | 2.5% | $41m | 1,667,661 | New |
| UroGen PharmaURGN | 2.1% | $34m | 933,415 | Held |
| MoonLake ImmunotherapeuticsMLTX | 1.9% | $31m | 1,606,967 | -11% |
| Palvella TherapeuticsPVLA | 1.9% | $31m | 204,027 | Held |
| Taysha Gene TherapiesTSHA | 1.9% | $31m | 4,500,000 | New |
| Syndax PharmaceuticalsSNDX | 1.8% | $29m | 1,333,523 | Held |
| Monte Rosa TherapeuticsGLUE | 1.7% | $28m | 1,161,081 | Held |
| Zura BioZURA | 1.6% | $26m | 4,472,843 | New |
| NateraNTRA | 1.5% | $25m | 92,638 | Held |
| Stoke TherapeuticsSTOK | 1.4% | $24m | 723,314 | -6% |
| Adlai NortyeANL | 1.4% | $22m | 1,936,291 | New |
| Belite BIOBLTE | 1.3% | $21m | 137,208 | +56% |
| Forte Biosciences | 1.3% | $21m | 987,448 | Held |
| Oric PharmaceuticalsORIC | 1.2% | $20m | 1,882,162 | +4% |
| Tarsus PharmaceuticalsTARS | 1.2% | $20m | 322,007 | -2% |
| AnnexonANNX | 1.2% | $20m | 3,544,354 | New |
| Bright Minds BiosciencesDRUG | 0.9% | $14m | 202,114 | -5% |
| Entrada TherapeuticsTRDA | 0.6% | $9m | 1,253,053 | New |
| Aclaris TherapeuticsACRS | 0.3% | $6m | 1,042,467 | +166% |
| Context TherapeuticsCNTX | <0.1% | $719,542 | 1,299,046 | -88% |
| Werewolf TherapeuticsHOWL | <0.1% | $28,851 | 80,142 | -93% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 184.1% since 30 June 2025.
Where the money is
Health care89.7%
Other10.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.